<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004078</url>
  </required_header>
  <id_info>
    <org_study_id>P9761</org_study_id>
    <secondary_id>NCI-2012-02310</secondary_id>
    <secondary_id>CDR0000067288</secondary_id>
    <secondary_id>POG-9761</secondary_id>
    <secondary_id>CCG-P9761</secondary_id>
    <secondary_id>COG-P9761</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00004078</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Children With Refractory Solid Tumors</brief_title>
  <official_title>Phase II Trial of Irinotecan in Children With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying irinotecan to see how well it works in treating children with&#xD;
      refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of irinotecan in children with refractory CNS or solid tumors.&#xD;
&#xD;
      II. Assess the toxicity, pharmacokinetics, and pharmacodynamics of this regimen in this&#xD;
      patient population.&#xD;
&#xD;
      III. Determine patient UGT1A1 genotype and correlate genotype with toxicity and&#xD;
      pharmacokinetic parameters of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of solid tumor (Ewings/PNET vs&#xD;
      neuroblastoma vs osteosarcoma vs rhabdomyosarcoma vs other solid tumors excluding lymphomas&#xD;
      and brain tumors) or brain tumor (medulloblastoma/PNET vs brain stem glioma vs ependymoma vs&#xD;
      other CNS tumors).&#xD;
&#xD;
      Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks&#xD;
      for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients are followed every 6 months for 4 years and then annually thereafter until death or&#xD;
      until patient enters another POG study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (PR or CR), recorded according to standard solid tumor response criteria</measure>
    <time_frame>Up to 8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, graded using the NCI CTCAE version 2.0</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of irinotecan hydrochloride</measure>
    <time_frame>Day 1 of course 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Craniopharyngioma</condition>
  <condition>Childhood Grade I Meningioma</condition>
  <condition>Childhood Grade II Meningioma</condition>
  <condition>Childhood Grade III Meningioma</condition>
  <condition>Childhood Infratentorial Ependymoma</condition>
  <condition>Childhood Oligodendroglioma</condition>
  <condition>Childhood Supratentorial Ependymoma</condition>
  <condition>Previously Treated Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (irinotecan hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irinotecan hydrochloride)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed CNS or solid tumors recurrent or refractory&#xD;
             to standard therapy&#xD;
&#xD;
               -  Solid tumors:&#xD;
&#xD;
                    -  Neuroblastoma&#xD;
&#xD;
                    -  Ewing's Sarcoma/peripheral primitive neuroectodermal tumor (PNET)&#xD;
&#xD;
                    -  Osteosarcoma&#xD;
&#xD;
                    -  Rhabdomyosarcoma&#xD;
&#xD;
                    -  Other extracranial solid tumors&#xD;
&#xD;
               -  CNS tumors:&#xD;
&#xD;
                    -  Medulloblastoma/PNET&#xD;
&#xD;
                    -  Ependymoma&#xD;
&#xD;
                    -  Brain stem glioma&#xD;
&#xD;
                    -  Other CNS tumor&#xD;
&#xD;
                    -  Intrinsic brain stem tumor (biopsy required only if previously treated with&#xD;
                       radiosurgery)&#xD;
&#xD;
                    -  Classic optic glioma (histologic requirement waived)&#xD;
&#xD;
          -  Measurable disease by imaging studies&#xD;
&#xD;
               -  No lesions assessable only by radionuclide scan&#xD;
&#xD;
          -  Previously irradiated lesions used to evaluate tumor response must show evidence of an&#xD;
             interim increase in size&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% if more than 10 years old&#xD;
&#xD;
          -  Performance status - Lansky 50-100% if 10 years or younger&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8 mg/dL&#xD;
&#xD;
          -  Inadequate peripheral blood counts due to bone marrow infiltration allowed&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 5 times normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
          -  No severe uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (8 weeks since prior nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Prior topotecan allowed&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  Concurrent dexamethasone for brain tumor patients allowed if on a stable or decreasing&#xD;
             dose for at least 2 weeks prior to study&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy&#xD;
&#xD;
          -  No other concurrent endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 8 weeks since prior extended radiotherapy (including evaluable lesions) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior total body radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent anticonvulsants&#xD;
&#xD;
          -  No concurrent medications that would interfere with the P-450 enzyme system function&#xD;
             (e.g., erythromycin, cimetidine, fluconazole)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Bomgaars</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Rhabdomyosarcoma, Embryonal</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

